Gefitinib
- PDF / 169,310 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 67 Downloads / 172 Views
1 S
Acquired drug resistance: case report A man in his 60s [exact age not stated] acquired resistance to gefitinib while being treated for non-small cell lung cancer (NSCLC) with leptomeningeal metastases (LMs). The man, who was diagnosed with pT1bN1M0 stage IIA NSCLC with LMs, started receiving treatment with gefitinib 250 mg/day [route not stated]. Additionally, he was treated with whole brain radiotherapy (WBRT). Subsequent MRI showed that the LMs had disappeared. However, approximately 43 months after treatment, carcinoembryonic antigen (CEA) levels increased. It appeared that he had acquired resistance to gefitinib, and the elevated CEA levels were not accompanied by systemic disease progression. The man was treated with erlotinib. Though, the CEA levels remained high, he was still free of significant recurrent disease 57 months following WBRT administration. Sakaguchi M, et al. Successful treatment of nonsmall cell lung cancer patients with leptomeningeal metastases using whole brain radiotherapy and tyrosine kinase inhibitors. 803519027 Journal of Cancer Research and Therapeutics 16: 930-932, No. 4, Jul-Sep 2020. Available from: URL: http://doi.org/10.4103/jcrt.JCRT_1343_16
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
